Monday, November 27, 2006 7:00:00 AM PDT | VentureDeal Staff
ATLANTA, GA -- Alimera Sciences announced the receipt of the second and final tranche of its Series B financing. The funding totaled $15.9 million and brings Series B funding to-date to $31.8 million. The company is developing ophthalmic pharmaceuticals and will use the funds to further develop it's stage III trial drug Medidur TM which the company claims treats diabetic macular edema. All previous Series B investors participated in the tranche, including BA Venture Partners, Intersouth Partners, Domain Associates, Venrock Partners and Polaris Venture Partners.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
